ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base

ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base

Portfolio
  • Existing investors and new investor Double Point Ventures join forces to support ImmunOs Therapeutics 
  • Investment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers

Sep 17, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-inclass therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.

Proceeds from the Series C will be used to further fund the ongoing clinical trial of ImmunOs’lead program IOS-1002 to completion of the Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD1 therapy KEYTRUDA® (pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy agent for the treatment of advanced solid tumors that simultaneously targets several immune checkpoints. It is based on a naturally occurring human leukocyte antigen (HLA) targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 and designed to activate both innate and adaptive immune cells to modulate the tumor microenvironment, potentially also enhancing the ebectiveness of existing IO treatments such as KEYTRUDA. 

* You can read the full PR by downloading the attached PDF